Irsko - angličtina - HPRA (Health Products Regulatory Authority)

sanofi-synthelabo ireland ltd - milrinone - tablets - 5 milligram

Irsko - angličtina - HPRA (Health Products Regulatory Authority)

sanofi-synthelabo ireland ltd - milrinone - 7.5 milligram

Irsko - angličtina - HPRA (Health Products Regulatory Authority)

sanofi-synthelabo ireland ltd - milrinone - tablets - 10 milligram

Indie - angličtina - Central Drugs Standard Control Organization

samarth - milrinone - inj - 10mg/10ml - amp.

Indie - angličtina - Central Drugs Standard Control Organization

gland ph. - milrinone - inj - 10mg/10ml - 10ml amp.

Indie - angličtina - Central Drugs Standard Control Organization

united bio. - milrinone - inj - 10mg/10ml - 1

Indie - angličtina - Central Drugs Standard Control Organization

vhb - milrinone - inj - 1mg - 1

Indie - angličtina - Central Drugs Standard Control Organization

sanofi aventis - milrinone - amp - 1mg/ml - 10ml

Austrálie - angličtina - Department of Health (Therapeutic Goods Administration)

astragrace corp pty ltd - royal jelly fresh -

Spojené státy - angličtina - NLM (National Library of Medicine)

physicians total care, inc. - anagrelide hydrochloride (unii: vns4435g39) (anagrelide - unii:k9x45x0051) - anagrelide 0.5 mg - anagrelide hydrochloride capsules are indicated for the treatment of patients with thrombocythemia, secondary to myeloproliferative disorders, to reduce the elevated platelet count and the risk of thrombosis and to ameliorate associated symptoms including thrombo-hemorrhagic events (see clinical studies , dosage and administration ). anagrelide is contraindicated in patients with severe hepatic impairment. exposure to anagrelide is increased 8 fold in patients with moderate hepatic impairment (see clinical pharmacology ). use of anagrelide in patients with severe hepatic impairment has not been studied (see also warnings, hepatic ).